{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:28:10Z","timestamp":1793734090300,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtct.2024.11.006","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T08:51:15Z","timestamp":1731574275000},"page":"77.e1-77.e20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS"],"prefix":"10.1016","volume":"31","author":[{"given":"Michael","family":"Radford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-6709","authenticated-orcid":false,"given":"Alejandro","family":"Garcia-Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8333-9132","authenticated-orcid":false,"given":"Rohail","family":"Badami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Grafodatskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7952-2279","authenticated-orcid":false,"given":"Elizabeth","family":"McCready","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2119-6626","authenticated-orcid":false,"given":"Dina","family":"Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwin","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-0924","authenticated-orcid":false,"given":"Kylie","family":"Lepic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2668-0449","authenticated-orcid":false,"given":"Tobias","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtct.2024.11.006_bib0001","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41409-022-01579-9","article-title":"Chimerism analysis for clinicians: a review of the literature and worldwide practices","volume":"57","author":"Blouin","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2024.11.006_bib0002","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.jtct.2024.11.006_bib0003","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2024.11.006_bib0004","doi-asserted-by":"crossref","first-page":"374.e1","DOI":"10.1016\/j.jtct.2022.04.009","volume":"28","author":"Klyuchnikov","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.11.006_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100673","article-title":"Is microchimerism a sign of imminent disease recurrence after allogeneic hematopoietic stem cell transplantation? A systematic review of the literature","volume":"44","author":"Haugaard","year":"2020","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.jtct.2024.11.006_bib0006","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.leu.2402017","article-title":"Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation","volume":"15","author":"Lion","year":"2001","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.jtct.2024.11.006_bib0007","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","article-title":"Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"104","author":"Baron","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2024.11.006_bib0008","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"20","key":"10.1016\/j.jtct.2024.11.006_bib0009","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2024.11.006_bib0010","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.11.006_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2024.11.006_bib0012","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.11.006_bib0013","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.11.006_bib0014","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2024.11.006_bib0015","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/S2352-3026(19)30220-0","volume":"7","author":"Walker","year":"2020","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.jtct.2024.11.006_bib0016","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European group for blood and marrow transplantation","volume":"114","author":"Kroger","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.11.006_bib0017","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2024.11.006_bib0018","unstructured":"Bolon YT, Atshan R, Allbee-Johnson M, Estrada-Merly N, Lee S. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. Available at: http:\/\/wwwcibmtrorg 2022. Accessed September 2024"},{"issue":"5","key":"10.1016\/j.jtct.2024.11.006_bib0019","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.bmt.1701119","article-title":"Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT","volume":"21","author":"Bader","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.11.006_bib0020","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.2004.05.198","article-title":"Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?","volume":"22","author":"Bader","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jtct.2024.11.006_bib0021","first-page":"801","article-title":"Chimerism status is a useful predictor of relapse after allogeneic stem cell transplantation for acute leukemia","volume":"88","author":"Barrios","year":"2003","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jtct.2024.11.006_bib0022","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/sj.bmt.1701604","article-title":"Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse","volume":"23","author":"Serrano","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2024.11.006_bib0023","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/bbmt.2001.v7.pm11669214","volume":"7","author":"Antin","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2024.11.006_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106173","article-title":"Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease","volume":"83","author":"Kinsella","year":"2019","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.jtct.2024.11.006_bib0025","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/bmt.2008.155","article-title":"Lack of utility of chimerism studies obtained 2-3 months after myeloablative hematopoietic cell transplantation for ALL","volume":"42","author":"Doney","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.11.006_bib0026","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.leukres.2014.02.001","article-title":"Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"38","author":"Bernal","year":"2014","journal-title":"Leuk Res"},{"issue":"5","key":"10.1016\/j.jtct.2024.11.006_bib0027","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.leukres.2013.01.010","article-title":"Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant","volume":"37","author":"Nikolousis","year":"2013","journal-title":"Leuk Res"},{"issue":"12","key":"10.1016\/j.jtct.2024.11.006_bib0028","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.bbmt.2020.07.013","article-title":"Early mixed lymphoid donor\/host chimerism is associated with improved transplant outcome in patients with primary or secondary myelofibrosis","volume":"26","author":"Deeg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2024.11.006_bib0029","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/bjh.14008","article-title":"Peripheral blood late mixed chimerism in leucocyte subpopulations following allogeneic stem cell transplantation for childhood malignancies: does it matter?","volume":"173","author":"Pichler","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2024.11.006_bib0030","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/sj.leu.2402311","article-title":"Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation","volume":"15","author":"Mattsson","year":"2001","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2024.11.006_bib0031","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/s41409-018-0176-7","article-title":"Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation","volume":"53","author":"Sellmann","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.11.006_bib0032","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/bloodadvances.2018025502","article-title":"Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells","volume":"3","author":"Kinsella","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.jtct.2024.11.006_bib0033","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2019000134","article-title":"PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade","volume":"3","author":"Ikegawa","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2024.11.006_bib0034","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbmt.2019.09.030","article-title":"Optimized timing of post-transplantation cyclophosphamide in MHC-haploidentical murine hematopoietic cell transplantation","volume":"26","author":"Wachsmuth","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2024.11.006_bib0035","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"The New England journal of medicine"},{"issue":"4","key":"10.1016\/j.jtct.2024.11.006_bib0036","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.leu.2403692","article-title":"Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies","volume":"19","author":"Lassaletta","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.jtct.2024.11.006_bib0037","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/bmt.2017.45","article-title":"Safety of pre-emptive donor lymphocyte infusions (DLI) based on mixed chimerism (MC) in peripheral blood or bone marrow subsets in children undergoing hematopoietic stem cell transplant (HSCT) for hematologic malignancies","volume":"52","author":"Liou","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"10.1016\/j.jtct.2024.11.006_bib0038","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.jtct.2024.11.006_bib0039","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"The lancet oncology"},{"issue":"11","key":"10.1016\/j.jtct.2024.11.006_bib0040","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1038\/leu.2017.242","article-title":"Phase I\/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)","volume":"31","author":"Bug","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jtct.2024.11.006_bib0041","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41409-021-01515-3","article-title":"Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia","volume":"57","author":"Schmid","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2024.11.006_bib0042","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1200\/JCO.20.01719","article-title":"Defining the role of donor lymphocyte infusion in high-risk hematologic malignancies","volume":"39","author":"Schmid","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007590?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724007590?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T04:43:38Z","timestamp":1740890618000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724007590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666636724007590"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.11.006","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early Mixed Donor Chimerism is a Strong Negative Prognostic Indicator in Allogeneic Stem Cell Transplant for AML and MDS","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}